Nov 28, 2017
|
Ardelyx and Kyowa Hakko Kirin Announce License Agreement for Tenapanor for Cardiorenal Diseases in Japan
|
Nov 21, 2017
|
Ardelyx Announces Updated Development Path for its Cardiorenal Pipeline
|
Nov 7, 2017
|
Ardelyx Reports Third Quarter 2017 Operating Results and Clinical Progress
|
Oct 16, 2017
|
Ardelyx Announces Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling
|
Oct 11, 2017
|
Ardelyx's Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018
|
Aug 9, 2017
|
Ardelyx Focuses Resources on Late-Stage Programs and Reports Second Quarter 2017 Operational Results
|
Aug 2, 2017
|
Ardelyx Announces Date of Second Quarter Financial Results and Presentation at Wedbush PacGrow Healthcare Conference
|
May 12, 2017
|
Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C
|
May 5, 2017
|
Ardelyx Reports First Quarter 2017 Operating Results and Highlights Recent Progress
|
Apr 18, 2017
|
Ardelyx To Present at Upcoming Spring Medical Meetings
|